FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
wasiiiigton,	D.C.	20049

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
ha	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Tanimoto Sarina</u>						2. Issuer Name and Ticker or Trading Symbol ARS Pharmaceuticals, Inc. [SPRY]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner					
	S PHARMA	irst)			04	3. Date of Earliest Transaction (Month/Day/Year) 04/19/2024								X Officer (give title Other (specify below) below) CHIEF MEDICAL OFFICER					
11682 EL CAMINO REAL, SUITE 120					_ 4.	4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line)													
(Street) SAN DII	EGO C	A	92130											X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	itate)	(Zip)			Rule	10b	5-1(c)	Tran	sac	tion Ind	cation	·						
						Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisf the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												d to satisfy	
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3)		2. Transactio Date (Month/Day/Y		/Year) Execu	xecution any	Deemed cution Date, ny nth/Day/Year)	Transaction Dispo			. Securities Acquired (A) or bisposed Of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of ndirect Beneficial Dwnership			
							Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)			Instr. 4)				
Common	Stock													3,276,8	854	Ι			
Common	Common Stock		04/19	04/19/2024				M		119,047	A	\$0.84	4,245,869		I		By Spouse		
Common	Stock			04/19/2024		4			M		69,444	A	\$1.44	4,315,313]	_	By Spouse	
Common	Stock													1,646,494		I L. C. R. U. D. Ja		Annuary 7, 2020 ⁽¹⁾	
Common Stock												1,848,499		I La Ta		By Lowenthal- Fanimoto Family Frust U/A DTD 4/3/2006 ⁽²⁾			
Common Stock												1,647,447		I I		By Sarina Fanimoto Charitable Remainder JniTrust Dated January 7, 2020 ⁽³⁾			
			Table II								posed of,			Owned					
1. Title of Derivative Security 2. Conversion Date (Month/Day/Year) 3. Transaction Date Execution (Month/Day/Year) (Month/Day/Year) 3. Transaction Date (Month/Day/Year) (Month/Day/Year)		ed 4. Date, Transactio		5. Number of Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownershi Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership t (Instr. 4)					
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amount or Number of Shares	unt (li ber		: 4)			
Stock Option (right to buy)	\$0.84	04/19/2024			М			119,047	(4)		12/16/2029	Common Stock	119,047	\$0	117	117,333		By Spouse	
Stock Option (right to buy)	\$1.44	04/19/2024			M			69,444	(4)		12/13/2031	Common Stock	69,444	\$0	166,936		I	By Spouse	

Explanation of Responses:

- 2. The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of the trust.
- 3. The Reporting Person is trustee of the trust.
- 4. 25% of the shares subject to the option vested on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date.

/s/ Kathleen Scott, Attorney-in-04/22/2024 **Fact**

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.